My main research interests are in genital and urinary cancers, and I lead a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med (2019) 380(12):1116-1127. PMID: 30779529
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet (2019) 393(10189):2404-2415. PMID: 31079938
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature (2018) 554(7693):544-548. PMID: 29443960
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med (2018) 24(6):749-757. PMID: 29867230
I am the lead for solid tumor research at Barts Cancer Institute. I also lead the genitourinary (GU) cancer group at BCI.
My work focuses on a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies. They exploit functional imaging and tissue collection.
Alongside these trials, our research focuses on correlation of novel biomarkers and aims to define markers that are of prognostic value and can predict response or resistance to therapy.
I have written over 100 peer review papers in this area and have grant income from national and international funding bodies.
I am on the editorial board of a number of journals and am part of the faculty for the major global oncology meetings.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Powles T, Kockx M, Rodriguez-Vida A et al. Nat Med (2019) (2)
PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in patients with metastatic renal cell carcinoma: Analysis of the randomized clinical trials Meteor and Cabosun Flaifel A, Xie W, Braun DA et al. Clinical Cancer Research (2019) 25(7) 6080-6088
Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches Song D, Powles T, Shi L et al. Journal of Pathology (2019) 249(7) 151-165
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Motzer RJ, Rini BI, McDermott DF et al. The Lancet Oncology (2019) 20(7) 1370-1385
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)(Figure presented.) De Bruijn RE, Mulders P, Jewett MA et al. European Urology (2019) 76(7) 437-440
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer Bamias A, Tzannis K, Bamia C et al. Oncologist (2019) 24(7) 1348-1355
Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer Martini A, Jia R, Ferket BS et al. Cancer (2019) 125(7) 3155-3163
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors Michaelson MD, Gupta S, Agarwal N et al. Oncologist (2019) 24(7) 1151-e817
Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ (European Journal of Cancer (2019) 108 (33–40), (S0959804918315399), (10.1016/j.ejca.2018.11.031)) Auvray M, Auclin E, Barthelemy P et al. European Journal of Cancer (2019) 119(7) 200-201
Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis Dabestani S, Beisland C, Stewart GD et al. European Urology Focus (2019) 5(7) 857-866For additional publications, please click here
I qualified from St Bartholomew’s Medical School in 1996 and trained in medical oncology at Imperial College. I completed post-graduate training in oncology in 2005 and received an MD from the University of London in 2006. My thesis was in mechanisms of resistance to therapy in urology cancers.